THERAPY DOSSIER · th-c427a781fb9e

Adalimumab

Biologic · TNF-alpha inhibitor (INHIBITOR; direct interaction)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: TNF-alpha inhibitor (INHIBITOR; direct interaction)
Target: CHEMBL1825
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: 2002
Development stage: Not recorded
ChEMBL record: CHEMBL1201580 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Adalimumab; Humira; Amgevita; Amjevita; Cyltezo; Hyrimoz; Imraldi; Hulio; Idacio; Yuflyma; D2E7
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02256462 ↗PHASE4completed

Pediatric Crohn's Disease Adalimumab Level-based Optimization Treatment (PAILOT) Trial

Crohn's Disease

Enrolment: 82 · Results not recorded

NCT02185014 ↗PHASE3completed

Long Term Efficacy, Safety, Tolerability of Repeated Adalimumab in Crohn's Disease

Crohn's Disease

Enrolment: 252 · Results not recorded

NCT03172325 ↗PHASE3completed

Phase III Trial of CinnoRA (Adalimumab) Versus Humira for Active RA

Active Rheumatoid Arthritis

Enrolment: 136 · Results not recorded

NCT04088409 ↗PHASE3active not recruiting

Oral Baricitinib vs Adalimumab in JIA-Associated Uveitis or Chronic Anterior Uveitis

Uveitis

Enrolment: 30 · Results not recorded

NCT06258915 ↗PHASE3not yet recruiting

Adalimumab vs Mycophenolate Mofetil in Steroid Dependent Non-infectious Uveitis

Non Infectious Uveitis

Enrolment: 120 · Results not recorded

NCT03970824 ↗PHASE1completed

Phase 1 Study to Compare PK and Safety of CT-P17 and Humira in Healthy Subjects

Healthy

Enrolment: 312 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30358007 ↗2018Reported benefit

Adalimumab mitigates ovarian ischemia-reperfusion injury in rats by regulating oxidative stress, apoptosis and resolution of inflammation.

RatIschaemia-reperfusionOther / unspecifiedWistar AlbinoFemalen = 40 rats in total, four groups

Model: Bilateral ovarian torsion-detorsion (ischaemia-reperfusion)

Adalimumab reduced tissue total oxidant status, oxidative stress index and nitric oxide, increased tissue total antioxidant status, lowered inflammation, vascular congestion and haemorrhage, and significantly decreased the apoptotic index. Serum oxidative stress markers and tissue malondialdehyde d…

Extraction: extract · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…